MetLife Investment Management
LCTX icon

MetLife Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

MetLife Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Buy
+110,301
New +$152K ﹤0.01% 2592
2024
Q3 		– Sell
-78,181
Closed -$78K – 2868
2024
Q2 		$78K Buy
78,181
+8,472
+12% +$9.36K ﹤0.01% 2688
2024
Q1 		$103K Buy
69,709
+955
+1% +$1.08K ﹤0.01% 2521
2023
Q4 		$74.9K Hold
68,754
– – ﹤0.01% 2720
2023
Q3 		$81.1K Hold
68,754
– – ﹤0.01% 2685
2023
Q2 		$96.9K Buy
+68,754
New +$95K ﹤0.01% 2699
2022
Q1 		– Sell
-49,379
Closed -$121K – 2753
2021
Q4 		$121K Buy
49,379
+32,752
+197% +$76.7K ﹤0.01% 2335
2021
Q3 		$41.9K Sell
16,627
-33,932
-67% -$87.1K ﹤0.01% 2538
2021
Q2 		$144K Buy
+50,559
New +$131K ﹤0.01% 2339

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MetLife Investment Management's LCTX Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 110,301 shares worth $144K. The stake represents ﹤0.01% of the portfolio and ranks #2592 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in LCTX as recently as Q2 2024.

MetLife Investment Management first reported a position in LCTX in Q2 2021 and has held it in 9 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • MetLife Investment Management held 110,301 shares of Lineage Cell Therapeutics worth $144K as of Q2 2026.
  • Lineage Cell Therapeutics was a new MetLife Investment Management position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2592 holding.
  • MetLife Investment Management first reported a position in Lineage Cell Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.